<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617500</article-id><article-id pub-id-type="pmc">5873780</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0030</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>External Validation of European System for Cardiac Operative Risk
Evaluation II (EuroSCORE II) for Risk Prioritization in an Iranian
Population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Atashi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Amini</surname><given-names>Shahram</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Tashnizi</surname><given-names>Mohammad Abbasi</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Moeinipour</surname><given-names>Ali Asghar</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Aazami</surname><given-names>Mathias Hossain</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tohidnezhad</surname><given-names>Fariba</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ghasemi</surname><given-names>Erfan</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Eslami</surname><given-names>Saeid</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Medical Informatics, Faculty of Medicine, Mashhad
University of Medical Sciences, Mashhad, Iran. </aff><aff id="aff2">
<label>2</label> Medical Informatics Department, Breast Cancer Research Center,
Moatamed Cancer Institute, ACECR, Tehran, Iran. </aff><aff id="aff3">
<label>3</label> Department of Anesthesiology and Critical Care, Mashhad University
of Medical Sciences, Mashhad, Iran. </aff><aff id="aff4">
<label>4</label> Department of Cardiac Surgery, Mashhad University of Medical
Sciences, Mashhad, Iran. </aff><aff id="aff5">
<label>5</label> Cardiac Anesthesia Research Center, Mashhad University of Medical
Sciences, Mashhad, Iran. </aff><aff id="aff6">
<label>6</label> Department of Biostatistics, School of Paramedical Sciences, Shahid
Beheshti University of Medical Sciences, Tehran, Iran. </aff><aff id="aff7">
<label>7</label> Pharmaceutical Research Center, Mashhad University of Medical
Sciences, Mashhad, Iran. </aff><aff id="aff8">
<label>8</label> Department of Medical Informatics, Academic Medical Center,
University of Amsterdam, Amsterdam, the Netherlands. </aff><author-notes><corresp id="c1">Correspondence Address: Shahram Amini, Department of Anesthesiology
and Critical Care, Cardiac Anesthesia Research Center, Emam Rreza Hospital, Ebne
Sina Street, Mashhad, Iran. E-mail: <email>aminish@mums.ac.ir</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>40</fpage><lpage>46</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The European System for Cardiac Operative Risk Evaluation II (EuroSCORE II)
is a prediction model which maps 18 predictors to a 30-day post-operative
risk of death concentrating on accurate stratification of candidate patients
for cardiac surgery.</p></sec><sec><title>Objective</title><p>The objective of this study was to determine the performance of the EuroSCORE
II risk-analysis predictions among patients who underwent heart surgeries in
one area of Iran.</p></sec><sec><title>Methods</title><p>A retrospective cohort study was conducted to collect the required variables
for all consecutive patients who underwent heart surgeries at Emam Reza
hospital, Northeast Iran between 2014 and 2015. Univariate and multivariate
analysis were performed to identify covariates which significantly
contribute to higher EuroSCORE II in our population. External validation was
performed by comparing the real and expected mortality using area under the
receiver operating characteristic curve (AUC) for discrimination assessment.
Also, Brier Score and Hosmer-Lemeshow goodness-of-fit test were used to show
the overall performance and calibration level, respectively.</p></sec><sec><title>Results</title><p>Two thousand five hundred eight one (59.6% males) were included. The observed
mortality rate was 3.3%, but EuroSCORE II had a prediction of 4.7%. Although
the overall performance was acceptable (Brier score=0.047), the model showed
poor discriminatory power by AUC=0.667 (sensitivity=61.90, and
specificity=66.24) and calibration (Hosmer-Lemeshow test,
<italic>P</italic>&#x0003c;0.01).</p></sec><sec><title>Conclusion</title><p>Our study showed that the EuroSCORE II discrimination power is less than
optimal for outcome prediction and less accurate for resource allocation
programs. It highlights the need for recalibration of this risk
stratification tool aiming to improve post cardiac surgery outcome
predictions in Iran.</p></sec></abstract><kwd-group><kwd>Mortality</kwd><kwd>Decision Support Techniques</kwd><kwd>Risk Assessment</kwd><kwd>Cardiac Surgical Procedures</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AUC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Area under the receiver
operating characteristic curve</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CCS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Canadian Cardiovascular
Society</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection factor</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EuroSCORE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= European System for
Cardiac Operative Risk Evaluation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RAMR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Risk-adjusted mortality
ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">STS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society of Thoracic
Surgeons</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>A growing literature shows the pervasiveness and importance of the need for reliable
information on the cost-effectiveness of adult cardiac surgeries. Moreover,
potential post-operative adverse events highlight the significance of perioperative
clinical decision making. Various prediction models have been developed aiming to
estimate risk-adjusted mortality, morbidity and length of intensive care unit stay
following cardiac surgeries<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. European System for Cardiac Operative Risk Evaluation
(EuroSCORE) is a risk stratification tool which incorporates 18 variables describing
patient, heart and proposed surgery to predict 30-day post operative risk of
death<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.
Predictive power of EuroSCORE II has been evaluated on different samples of target
population in European countries. Vast majority of these studies have reported
acceptable calibration (How many patients with a risk prediction of x% have
experienced the outcome?) and discrimination (Who are the patients who have
experienced the outcome associated with higher risk predictions and who are those
that do not?) measures in comparison to Society of Thoracic Surgeons (STS)
[esp. for patients undergoing coronary artery bypass grafting (CABG)
procedure<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>].</p><p>An international evaluation study was performed by Roques et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>, in 2000, to assess the
predictive ability of EuroSCORE II on 18676 patients from six European countries
(Germany, Spain, England, France, Italy, and Finland). Despite clinical and
epidemiological differences, EuroSCORE II provided acceptable predictions for all
datasets (esp. for Spanish patients). Geissler et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> compared six prediction
models using a single-center 2-year dataset, which resulted in the best performance
measures for EuroSCORE II. While previous studies published admissible application
of EuroSCORE II for patients undergoing CABG<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>,
conflict reports exist for Australian samples<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>Similar studies in Iran reflect poor applicability of EuroSCORE II within patients
undergoing different types of cardiac surgeries<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.
Diverse surgical techniques and potential risk factors already have been stabilized
in different communities may mislead prediction models and result in erroneous
interpretations. Thus, mathematical localization studies are required in different
geographical borders to assure its proper predictive function before routine
clinical use<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.
This study is conducted to investigate the accuracy of quantitative prioritization
scores estimated by EuroSCORE II in an Iranian population.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Participants and Setting</title><p>A retrospective single-center cohort study was conducted to include all
consecutive patients undergoing cardiac surgeries at Emam Reza hospital,
Northeast Iran from January 1, 2014 to December 31, 2015. Once the patient was
hospitalized a cardiologist or a general physician evaluated pre- peri- and
postoperative state to fill out the pre-designed structural paper form.</p><p>A total of 2907 patients were included and 30-day outcome was discovered using
hospital information system or direct contact with patients' family. About 11.2%
(N=326) of records were excluded due to major variables' missing values and all
data items were rechecked to verify their consistency, reliability and
integrity. In some cases (less than 3% of records) by the physicians'
recommendation, the missing data were imputed with normal values.</p></sec><sec><title>Statistical Analysis</title><p>First, univariate and multivariate analysis of relevant EuroSCORE II prognostic
factors were performed aiming to identify significant covariates which
contributed to higher risk. EuroSCORE II was calculated and inserted in dataset
using online calculator (Available at: <ext-link ext-link-type="uri" xlink:href="http://riskcalc.sts.org/stswebriskcalc/#">http://riskcalc.sts.org/stswebriskcalc/#</ext-link>). The data were
aggregated in a unique electronic dataset, summarized considering the
demographic and clinical characteristics and were used for statistical analysis.
The relation of each variable was addressed and the number of patients due to
different values were compared to the original EuroSCORE II population. Then,
the overall model performance was reported using Brier Score (A score function
which measures the closeness of predictions to actual outcomes and result in a
value from 0 for a perfect model to 0.25 for a non-informative
model)<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The area under the receiver operating
characteristic curve (AUC) statistic was used to indicate the discriminative
ability of model (while 1 refers to perfect discrimination, a value of 0.5 shows
random classification). The Hosmer-Lemeshow goodness-of-fit test was employed to
test the fitness of model to data by comparing observed to predicted mortality
by decile of predicted probability)<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Analysis were performed using Medcalc-13.3.3.0
and R-3.3.1 (Resource Selection package).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patients' Baseline Characteristics</title><p>The mean age among the total of 2581 patients was 56.3&#x000b1;13.88 years
(minimum=17 and maximum=93). The mortality rate was 3.3% (N=84). The mean height
and weight of patients were 1.64&#x000b1;0.1 meters and 68.4&#x000b1;13.4
kilograms, respectively. About 7.8% (N=201) of patients aged 75 years and older
and 22.2% (N=572) were diabetic. While 6.1% (N=158) were involved with a type of
chronic kidney disease, 15.1% (N=24) underwent dialysis regularly; 10.6% (N=274)
were current or past smokers and 2.2% (N=56) of patients were diagnosed with
COPD. <xref ref-type="table" rid="t1">Table 1</xref> summarizes some comparable
information of our patients with the original EuroSCORE II population.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Comparison of demographic and comorbidity characteristics between the
original EuroSCORE II population and an Iranian sample<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Frequencies (%) or mean (SD)
[range] of original EuroSCORE II Population
(N=22381)</th><th align="center" rowspan="1" colspan="1">Frequencies (%) or mean (SD)
[range] of our Population (N=2581)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age</td><td align="center" rowspan="1" colspan="1">64.6 (12.5) [18-95]</td><td align="center" rowspan="1" colspan="1">56.3 (13.88) [17-94]</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">Female</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">6919 (30.9%)</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">1044 (40.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">15462 (69.1%)</td><td align="center" rowspan="1" colspan="1">1537 (59.6%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Height (cm)&#x000a0;</td><td align="center" rowspan="1" colspan="1">168.5 (9.6) [100-213]</td><td align="center" rowspan="1" colspan="1">164.1 (10.0) [104-199]</td></tr><tr><td align="left" colspan="2" rowspan="1">Weight (kg)&#x000a0;</td><td align="center" rowspan="1" colspan="1">77.9 (15.9) [30-182]</td><td align="center" rowspan="1" colspan="1">68.4 (13.4) [28-132]</td></tr><tr><td align="left" colspan="2" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27.4 (4.8) [9.6-82.6]</td><td align="center" rowspan="1" colspan="1">25.4 (4.8) [10.1-62.6]</td></tr><tr><td align="left" colspan="2" rowspan="1">Diabetes on insulin</td><td align="center" rowspan="1" colspan="1">5643 (25.2%)</td><td align="center" rowspan="1" colspan="1">572 (22.2%)</td></tr><tr><td align="left" rowspan="3" colspan="1">NYHA</td><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">Class II</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">NA</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">1008 (37.0%)</td></tr><tr><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">Class III</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">NA</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">957 (37.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Class IV</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">96 (3.6%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Chronic pulmonary disease</td><td align="center" rowspan="1" colspan="1">2384 (10.7%)</td><td align="center" rowspan="1" colspan="1">56 (2.2%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Serum creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.13 (0.92)</td><td align="center" rowspan="1" colspan="1">1.09 (0.98)</td></tr><tr><td align="left" rowspan="2" colspan="1">Renal failure</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">&#x000a0;</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">108 (0.5%)</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">158 (6.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">23 (0.9%)</td></tr><tr><td align="left" rowspan="3" colspan="1">LV function (ejection fraction)</td><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">EF&#x02264;50</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">NA</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">1150 (44.6%)</td></tr><tr><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">51-70</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">NA</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">782 (30.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">EF&#x02264;70</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">20 (0.8%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Recent MI</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">161 (6.2%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Pulmonary hypertension</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">190 (7.3%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Previous cardiac surgery</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">8 (0.3%)</td></tr><tr><td align="left" rowspan="4" colspan="1">Urgency</td><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">Urgent operation</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">4135 (18.5%)</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">None</td></tr><tr><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">Emergency</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">972 (4.3%)</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">None</td></tr><tr><td style="border-bottom:hidden" align="left" rowspan="1" colspan="1">Elective</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">17 165 (76.7%)</td><td style="border-bottom:hidden" align="center" rowspan="1" colspan="1">2581 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Salvage</td><td align="center" rowspan="1" colspan="1">109 (0.5%)</td><td align="center" rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>NA=not available; BMI=body mass index; NYHA=New York Heart
Association functional classification; LV=left ventricle;
MI=myocardial infarction</p></fn></table-wrap-foot></table-wrap><p>As all procedures were elective operations, there were no urgent surgeries. Also,
23 patients undergoing valve surgery were suffering from active endocarditis,
extra cardiac arteriopathy. Poor mobility was observed in 48 patients. No
patient with Canadian Cardiovascular Society (CCS) class 4 or with critical
preoperative state was observed. Also, none of surgeries were on thoracic aorta.
Some other details are presented in <xref ref-type="table" rid="t1">Tables
1</xref> and <xref ref-type="table" rid="t2">2</xref>. As these patients had
no mortality, these factors were excluded for regression analysis. The
univariate and multivariate analysis are presented in <xref ref-type="table" rid="t3">Table 3</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>EuroSCORE II characteristics by patients' demographic and clinical
characteristics; number of patients and relation with mortality. The
expected and observed mortality can also be compared by any
variable<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Number of Patients N (%)</th><th align="center" rowspan="1" colspan="1">Mortality N (%)</th><th align="center" rowspan="1" colspan="1">Mortality Predicted truly (N) by EuroSCORE
II</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">1537 (59.6%)</td><td align="center" rowspan="1" colspan="1">40 (47.6%)</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">1044 (40.4%)</td><td align="center" rowspan="1" colspan="1">44 (52.4%)</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="5" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x02264;20</td><td align="center" rowspan="1" colspan="1">35 (1.4%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">21-40</td><td align="center" rowspan="1" colspan="1">301 (11.7%)</td><td align="center" rowspan="1" colspan="1">6 (7.1%)</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">41-60</td><td align="center" rowspan="1" colspan="1">1215 (47.1%)</td><td align="center" rowspan="1" colspan="1">30 (35.7%)</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="center" rowspan="1" colspan="1">61-80</td><td align="center" rowspan="1" colspan="1">979 (37.9%)</td><td align="center" rowspan="1" colspan="1">45 (53.6%)</td><td align="center" rowspan="1" colspan="1">31</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;80</td><td align="center" rowspan="1" colspan="1">46 (1.8%)</td><td align="center" rowspan="1" colspan="1">3 (3.6%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="5" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">&#x02264;18.5</td><td align="center" rowspan="1" colspan="1">120 (4.6%)</td><td align="center" rowspan="1" colspan="1">10 (11.9%)</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="center" rowspan="1" colspan="1">[18.5-23]</td><td align="center" rowspan="1" colspan="1">608 (23.6%)</td><td align="center" rowspan="1" colspan="1">21 (25%)</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="center" rowspan="1" colspan="1">[23-25]</td><td align="center" rowspan="1" colspan="1">437 (16.9%)</td><td align="center" rowspan="1" colspan="1">10 (11.9%)</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="center" rowspan="1" colspan="1">[25-30]</td><td align="center" rowspan="1" colspan="1">832 (32.2%)</td><td align="center" rowspan="1" colspan="1">28 (33.4%)</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;30</td><td align="center" rowspan="1" colspan="1">364 (14.1%)</td><td align="center" rowspan="1" colspan="1">7 (8.4%)</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="13" colspan="1">Valve Surgery (weight of the
intervention)</td><td align="center" rowspan="1" colspan="1">Isolated CABG</td><td align="center" rowspan="1" colspan="1">2071 (80.2%)</td><td align="center" rowspan="1" colspan="1">54 (64.3%)</td><td align="center" rowspan="1" colspan="1">37</td></tr><tr><td align="center" rowspan="1" colspan="1">AVR</td><td align="center" rowspan="1" colspan="1">76 (2.9%)</td><td align="center" rowspan="1" colspan="1">2 (2.4%)</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">MVR</td><td align="center" rowspan="1" colspan="1">195 (7.6%)</td><td align="center" rowspan="1" colspan="1">14 (16.7%)</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="center" rowspan="1" colspan="1">TVR</td><td align="center" rowspan="1" colspan="1">16 (0.6%)</td><td align="center" rowspan="1" colspan="1">2 (2.4%)</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">MVR+TVR</td><td align="center" rowspan="1" colspan="1">54 (2.1%)</td><td align="center" rowspan="1" colspan="1">4 (4.7%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">AVR+MVR</td><td align="center" rowspan="1" colspan="1">47 (1.8%)</td><td align="center" rowspan="1" colspan="1">3 (3.6%)</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">ASD+TVR</td><td align="center" rowspan="1" colspan="1">10 (0.4%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">ASD</td><td align="center" rowspan="1" colspan="1">7 (0.3%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">AVR+MVR+TVR</td><td align="center" rowspan="1" colspan="1">18 (0.7%)</td><td align="center" rowspan="1" colspan="1">1 (1.2%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">PVR</td><td align="center" rowspan="1" colspan="1">10 (0.4%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">2 procedures</td><td align="center" rowspan="1" colspan="1">122 (4.7%)</td><td align="center" rowspan="1" colspan="1">7 (8.3%)</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="center" rowspan="1" colspan="1">3 procedures</td><td align="center" rowspan="1" colspan="1">19 (0.7%)</td><td align="center" rowspan="1" colspan="1">1 (1.2%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">77 (3%)</td><td align="center" rowspan="1" colspan="1">4 (4.7%)</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="3" colspan="1">Ejection fraction</td><td align="center" rowspan="1" colspan="1">&#x02264;50</td><td align="center" rowspan="1" colspan="1">1150 (44.6%)</td><td align="center" rowspan="1" colspan="1">64 (76.1%)</td><td align="center" rowspan="1" colspan="1">31</td></tr><tr><td align="center" rowspan="1" colspan="1">51-70</td><td align="center" rowspan="1" colspan="1">782 (30.3%)</td><td align="center" rowspan="1" colspan="1">19 (22.6%)</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;70</td><td align="center" rowspan="1" colspan="1">20 (0.8%)</td><td align="center" rowspan="1" colspan="1">1 (1.2%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="2" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">572 (22.2%)</td><td align="center" rowspan="1" colspan="1">32 (38.1%)</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2009 (77.8%)</td><td align="center" rowspan="1" colspan="1">52 (61.9%)</td><td align="center" rowspan="1" colspan="1">37</td></tr><tr><td align="left" rowspan="2" colspan="1">COPD</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">56 (2.2%)</td><td align="center" rowspan="1" colspan="1">3 (3.6%)</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2525 (97.8%)</td><td align="center" rowspan="1" colspan="1">81 (96.4%)</td><td align="center" rowspan="1" colspan="1">51</td></tr><tr><td align="left" rowspan="2" colspan="1">Mortality</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">2497 (96.7%)</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" rowspan="1" colspan="1">Dead</td><td align="center" rowspan="1" colspan="1">84 (3.3%)</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">56</td></tr><tr><td align="left" rowspan="2" colspan="1">Previous cardiac surgery</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">8 (0.3%)</td><td align="center" rowspan="1" colspan="1">3 (3.6%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2573 (99.7%)</td><td align="center" rowspan="1" colspan="1">81 (96.4%)</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="2" colspan="1">Recent MI</td><td align="center" rowspan="1" colspan="1">&#x000a0; Yes</td><td align="center" rowspan="1" colspan="1">161 (6.2%)</td><td align="center" rowspan="1" colspan="1">7 (8.3%)</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0; No</td><td align="center" rowspan="1" colspan="1">2420 (93.8%)</td><td align="center" rowspan="1" colspan="1">77 (91.7%)</td><td align="center" rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="3" colspan="1">NYHA</td><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; Class II</td><td align="center" rowspan="1" colspan="1">1008 (37.0%)</td><td align="center" rowspan="1" colspan="1">7 (8.3%)</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; Class III</td><td align="center" rowspan="1" colspan="1">957 (37.1%)</td><td align="center" rowspan="1" colspan="1">24 (28.5%)</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; Class IV</td><td align="center" rowspan="1" colspan="1">96(3.6%)</td><td align="center" rowspan="1" colspan="1">4 (4.7%)</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="2" colspan="1">Renal failure</td><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; Yes</td><td align="center" rowspan="1" colspan="1">158 (6.1%)</td><td align="center" rowspan="1" colspan="1">14 (16.6%)</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; No</td><td align="center" rowspan="1" colspan="1">2423 (93.9%)</td><td align="center" rowspan="1" colspan="1">70 (83.3%)</td><td align="center" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="2" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; Yes</td><td align="center" rowspan="1" colspan="1">23 (0.9%)</td><td align="center" rowspan="1" colspan="1">2 (2.4%)</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; No</td><td align="center" rowspan="1" colspan="1">2558 (99.1%)</td><td align="center" rowspan="1" colspan="1">82 (97.6%)</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr><td align="left" rowspan="2" colspan="1">Pulmonary hypertension</td><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; Yes</td><td align="center" rowspan="1" colspan="1">190 (7.3%)</td><td align="center" rowspan="1" colspan="1">15 (17.9%)</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;&#x000a0; No</td><td align="center" rowspan="1" colspan="1">2391 (92.6%)</td><td align="center" rowspan="1" colspan="1">64 (82.1%)</td><td align="center" rowspan="1" colspan="1">46</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>BMI=body mass index; CABG=coronary artery bypass grafting; AVR=aortic
valve replacement; MVR=mitral valve replacement; TVR=tricuspid valve
replacement; ASD=atrial septal defect; PVR=pulmonary valve
replacement; COPD=chronic obstructive pulmonary disease; N/A=not
applicable; MI=myocardial infarction</p></fn><fn id="TFN3"><p><sup>a</sup>Analysis by independent-samples t test.</p></fn><fn id="TFN4"><p><sup>b</sup>Analysis by one-way ANOVA.</p></fn><fn id="TFN5"><p>Sum of percentages may not result in 100% due to missing data.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Univariate and multivariate analysis of EuroSCORE II prognostic
factors[2].</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">Characteristic</th><th style="border-bottom:hidden" align="center" rowspan="1" colspan="1">Mean &#x000b1;
SD</th><th align="center" colspan="2" rowspan="1">Univariate Analysis</th><th align="center" colspan="2" rowspan="1">Multivariate Analysis<sup><xref ref-type="table-fn" rid="TFN6">a</xref></sup></th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x003b2; (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">&#x003b2; (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age (year)<sup><xref ref-type="table-fn" rid="TFN6">a</xref></sup></td><td align="center" rowspan="1" colspan="1">56.3&#x000b1;13.88</td><td align="center" rowspan="1" colspan="1">0.063 (0.058 to 0.068)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.058 (0.051 to 0.065)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">3.5&#x000b1;1.95</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="2" align="center" valign="top" colspan="1">&#x0003c;0.001&#x000a0;</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1;2.16</td><td align="center" rowspan="1" colspan="1">-0.88 (-1.05 to -0.72)</td><td align="center" rowspan="1" colspan="1">-0.82 (-0.98 to -0.66)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="4" colspan="1">Creatinine clearance</td><td align="center" rowspan="1" colspan="1">&#x0003c;50</td><td align="center" rowspan="1" colspan="1">4.4&#x000b1;2.16</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="4" align="center" valign="top" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">50-85</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;1.99</td><td align="center" rowspan="1" colspan="1">-1.49 (-1.70 to -1.28)</td><td align="center" rowspan="1" colspan="1">-0.92 (-1.13 to -0.71)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;85</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;1.53</td><td align="center" rowspan="1" colspan="1">-2.57 (-2.8 to -2.34)</td><td align="center" rowspan="1" colspan="1">-1.06 (-1.32 to -0.79)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">3.0&#x000b1;2.31</td><td align="center" rowspan="1" colspan="1">-1.33 (-2.12 to -0.55)</td><td align="center" rowspan="1" colspan="1">-0.78 (-1.73 to -0.02)</td><td align="center" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="2" colspan="1">Chronic lung disease</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;2.11</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="2" align="center" valign="top" colspan="1">0.061</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">3.5&#x000b1;2.43</td><td align="center" rowspan="1" colspan="1">0.54 (-0.03 to 1.10)</td><td align="center" rowspan="1" colspan="1">0.15 (-0.31 to 0.61)</td><td align="center" rowspan="1" colspan="1">0.529</td></tr><tr><td align="left" rowspan="2" colspan="1">Diabetes on insulin</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">3.0&#x000b1;2.12</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="2" align="center" valign="top" colspan="1">0.859</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;2.14</td><td align="center" rowspan="1" colspan="1">-0.02 (-0.22 to 0.18)</td><td align="center" rowspan="1" colspan="1">-0.19 (-0.37 to -0.01)</td><td align="center" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" rowspan="4" colspan="1">NYHA</td><td align="center" rowspan="1" colspan="1">Class I</td><td align="center" rowspan="1" colspan="1">2.4&#x000b1;1.97</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="4" align="center" valign="top" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Class II</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;2.18</td><td align="center" rowspan="1" colspan="1">0.47 (0.18 to 0.77)</td><td align="center" rowspan="1" colspan="1">0.2 (-0.002 to 0.40)</td><td align="center" rowspan="1" colspan="1">0.052</td></tr><tr><td align="center" rowspan="1" colspan="1">Class III</td><td align="center" rowspan="1" colspan="1">3.3&#x000b1;2.09</td><td align="center" rowspan="1" colspan="1">0.86 (0.56 to 1.17)</td><td align="center" rowspan="1" colspan="1">0.14 (-0.07 to 0.35)</td><td align="center" rowspan="1" colspan="1">0.199</td></tr><tr><td align="center" rowspan="1" colspan="1">Class IV</td><td align="center" rowspan="1" colspan="1">3.8&#x000b1;1.98</td><td align="center" rowspan="1" colspan="1">1.44 (0.81 to 2.07)</td><td align="center" rowspan="1" colspan="1">0.52 (0.08 to 0.95)</td><td align="center" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="3" colspan="1">Left ventricular function</td><td align="center" rowspan="1" colspan="1">&#x02264;50</td><td align="center" rowspan="1" colspan="1">3.5&#x000b1;2.19</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="3" align="center" valign="top" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">51-70</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;1.84</td><td align="center" rowspan="1" colspan="1">-1.22 (-1.40 to -1.03)</td><td align="center" rowspan="1" colspan="1">-0.87 (-1.03 to -0.70)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;70</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 1.76</td><td align="center" rowspan="1" colspan="1">-1.52 (-2.43 to -0.61)</td><td align="center" rowspan="1" colspan="1">-1.37 (-2.06 to -0.69)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="2" colspan="1">Recent myocardial infarction</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;2.07</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="2" align="center" valign="top" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">4.7&#x000b1;2.19</td><td align="center" rowspan="1" colspan="1">1.81 (1.48 to 2.14)</td><td align="center" rowspan="1" colspan="1">1.86 (1.56 to 2.15)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="2" colspan="1">Pulmonary hypertension</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;2.03</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="2" align="center" valign="top" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">5.2&#x000b1;1.99</td><td align="center" rowspan="1" colspan="1">2.41 (2.11 to 2.71)</td><td align="center" rowspan="1" colspan="1">2.04 (1.77 to 2.31)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="4" colspan="1">Weight of the intervention</td><td align="center" rowspan="1" colspan="1">Isolated CABG</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;2.06</td><td align="center" rowspan="1" colspan="1">1 [References]</td><td rowspan="4" align="center" valign="top" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1 [Reference]</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">Single non-CABG</td><td align="center" rowspan="1" colspan="1">4.1&#x000b1;2.02</td><td align="center" rowspan="1" colspan="1">1.38 (1.14 to 1.62)</td><td align="center" rowspan="1" colspan="1">1.48 (1.25 to 1.72)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">2 Procedures</td><td align="center" rowspan="1" colspan="1">4.2&#x000b1;1.93</td><td align="center" rowspan="1" colspan="1">1.55 (1.21 to 1.90)</td><td align="center" rowspan="1" colspan="1">1.89 (1.56 to 2.22)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">3 Procedures</td><td align="center" rowspan="1" colspan="1">4.1&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">1.45 (0.74 to 2.15)</td><td align="center" rowspan="1" colspan="1">1.58 (0.91 to 2.25)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><label>a</label><p>Using linear regression, all variables were found to be associated
with EuroSCORE II, except for chronic lung disease, diabetes on
insulin, and NYHA.</p></fn><fn id="TFN7"><p>NYHA=New York Heart Association; CABG=coronary artery bypass
graft</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Patients' Heart Status</title><p>Using New York Heart Association (NYHA), 37.1% (N=957) were classified as stage
III cardiac failure patients, 6.2% (N=161) patients had a previous congestive
heart failure during three months before surgery, 1% (N=26) of patients had
atrial fibrillation. While 61.4% of surgeries were on-pump, the rest of
procedures were performed off-pump. <xref ref-type="table" rid="t2">Table
2</xref> shows more information about biological and clinical
characteristics of patients.</p></sec><sec><title>Performance Measures</title><p>As mentioned before, the overall mortality was 3.3%. When applied to the current
data set, the EuroSCORE II predicted a mortality of 4.7%. This means that the
current risk-adjusted mortality ratio (RAMR=observed/predicted) for the previous
additive model is about 0.67 and not adequately enough for outcome prediction or
resource allocation programs.</p><p>The Brier Score lower than 0.05 indicates acceptable overall performance.
However, poor discrimination may be revealed by AUC=0.667 (cut off=3.0,
sensitivity=61.90, and specificity=66.24). Also, the Hosmer-Lemeshow test showed
unacceptable matching of predicted probabilities to observed events
(<italic>P</italic>-value&#x0003c;0.01) (<xref ref-type="table" rid="t4">Table
4</xref>). Performance measures of EuroSCORE II are presented in <xref ref-type="fig" rid="f1">Figure 1</xref> and <xref ref-type="table" rid="t4">Table 4</xref>.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Performance measures calculated for EuroSCORE II scoring system.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Scoring System</th><th align="center" rowspan="1" colspan="1">Overall Performance</th><th align="center" colspan="5" rowspan="1">Discrimination</th><th align="center" rowspan="1" colspan="1">Calibration</th></tr><tr><th align="center" rowspan="1" colspan="1">Brier Score<break/>(min-max)
[STD]</th><th align="center" rowspan="1" colspan="1">AUC</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sensitivity</th><th align="center" rowspan="1" colspan="1">Specificity</th><th align="center" rowspan="1" colspan="1">H-L Test</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">EuroSCORE II</td><td align="center" rowspan="1" colspan="1">0.047 (0.0-1.0) [0.12]</td><td align="center" rowspan="1" colspan="1">0.667</td><td align="center" rowspan="1" colspan="1">0.0307</td><td align="center" rowspan="1" colspan="1">0.648-0.685</td><td align="center" rowspan="1" colspan="1">0.619</td><td align="center" rowspan="1" colspan="1">0.662</td><td align="center" rowspan="1" colspan="1">Chi<sup>2</sup>(8)=936.66,
<italic>P</italic>&#x0003c;0.01</td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><p>AUC=area under the ROC curve; SE=standard error; CI=confidence
interval, H-L=Hosmer-Lemeshow</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Area under the ROC curve for EuroSCORE II.</p></caption><graphic xlink:href="rbccv-33-01-0040-g01"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec><title>Main Finding</title><p>Our single-center study, based on consecutive patients who underwent cardiac
surgery revealed that EuroSCORE II demonstrated a moderate statistical overall
performance with poor discrimination and calibration measures remain as
concerning issues regarding 30-day post-operative mortality prediction after
adult cardiac surgery. The analysis of ROC curve showed that the EuroSCORE II
discrimination power is less than optimal (AUC=0.667) for outcome prediction and
less accurate for resource allocation programs, because, references consider an
AUC value more than 0.7 as an acceptable value for least useful prediction
models<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Although, the Brier score less than 0.05 indicates good
overall performance for the model<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>, the Hosmer-Lemeshow test showed unacceptable
matching of predicted probabilities to observed events. In general, EuroSCORE II
did not predict the outcome for our population as well as it did for the
European populations. Thus, recalibration process seems to be essential for
Iranian population prior to daily clinical use.</p><p>It is well known that risk assessment is central in the evaluation of the
perioperative risk. The application of risk stratification tools gives an
objective appraisal of risk for both physicians and patients and presents a good
estimation for allocation of resources. However, some features may not be fully
covered by the models including center-to-center variability in outcomes, type
of surgery required and inherent complexity of some diseases<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. On the other hand,
the patient populations defer significantly between institutions and countries.
Thus, the comparison of absolute numbers such as the mortality rates is not
feasible. A large variety of risk scores have been developed due to differences
in patient populations and comparisons of observed mortality versus expected
mortality have been reported<sup>[<xref rid="r15" ref-type="bibr">15</xref>-<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p></sec><sec><title>Comparison to Similar Studies</title><p>EuroSCORE was first developed in 1999 to estimate postsurgical mortality in a
European population who underwent cardiac surgery (70% of procedures were
CABG)<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.
A meta-analysis by Parolari et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> revealed poor performance of EuroSCORE II in
valve surgery, in 2010. Moreover, as the quality of medical techniques continues
to improve over time, model expiration was considered as an inevitable topic in
this area <sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r20" ref-type="bibr">20</xref>]</sup>. To address the surgical type bias in the
modified version of model, reasonable number of patients who experienced CABG
and valve surgeries were included in the development dataset<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The new version of
EuroSCORE reflected acceptable discrimination power among both European and
non-European samples<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r21" ref-type="bibr">21</xref>-<xref rid="r23" ref-type="bibr">23</xref>]</sup>. The new model also provided more acceptable
predictions for surgeries other than CABG<sup>[<xref rid="r21" ref-type="bibr">21</xref>-<xref rid="r23" ref-type="bibr">23</xref>]</sup>. However, evaluation studies in Iran reported poor
performance measures for both EuroSCORE I and II<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Further studies concentrating on recalibrated
version of the model published unacceptable results<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>.</p><p>The observed 30-day mortality rate in our sample (3.3%) was similar to those
published by Roques et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> (3.4%), Nashef et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> (3.9%), Geissler et
al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>
(4%), and Pitk&#x000e4;nen et al.<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup> (2%). While Mir Mohammad Sadeghi et
al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>
reported similar mortality rate in Isfahan (central Iran), four years later
Jamaati et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> evaluated EuroSCORE II on a sample containing 12.2
mortality rate. An AUC of 66.7% in our study is lower than all similar studies
including 78% by Geissler et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, 77% by Pitk&#x000e4;nen et al.<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>, and 75.4% by Antunes et
al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.
This is while similar studies in Iran confirmed the poor discriminative ability
of EuroSCORE II<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Currently, a great interest for prediction models as powerful tools for outcome
prediction, cost-effectiveness strategies, reasonable resource allocation, and
consequently quality control process have been growing<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>.</p><p>Due to the results of our study, despite the little differences between two
populations (<xref ref-type="table" rid="t1">Tables 1</xref> to <xref ref-type="table" rid="t3">3</xref>) the EuroSCORE II may not be completely
reliable for risk periodization or resource allocation programs in Iran. Poor
performance measures for EuroSCORE II highlights the need for reformulating this
risk stratification tool aiming to improve post cardiac surgery outcome
predictions in Iran. It may be done by calibrating mortality risk scoring model
(<italic>e.g.</italic> EuroSCORE model) for the region or creating new
models with accurate localized parameter sets<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p></sec><sec><title>Limitation</title><p>Although sampling was done in one of the largest hospitals performing various
cardiac procedures and the study has adequate sample size, including just one
center may affect the generalizability of results to the entire country.</p></sec><sec><title>Future Studies</title><p>Regarding the key prognostic role of prediction models, further investigation of
clinical risk factors and recalibration process seems to be essential on large
samples of target population from different centers around country aiming to
improve outcome predictions.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Our study showed that the EuroSCORE II discrimination power is less than optimal for
outcome prediction and less accurate for resource allocation programs. It highlights
the need for recalibration this risk stratification tool aiming to improve post
cardiac surgery outcome predictions in Iran.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; data gathering management;
final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAT</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; data gathering management;
final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AAM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; data gathering management;
final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MHA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; data gathering management;
final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FT</td><td align="left" valign="top" rowspan="1" colspan="1">Statistical analysis and interpretation of
data for the work; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EG</td><td align="left" valign="top" rowspan="1" colspan="1">Statistical analysis and interpretation of
data for the work; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SE</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; data gathering management;
final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Mashhad University of Medical Sciences, Mashhad,
Iran.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENT</title><p>The authors would like to express their appreciation to the staff of cardiac surgery
ICU of Emam Reza hospital, Mashhad, for their tremendous support in data collection.
We thank Proff. Ameen Abu-Hanna for remarks on an earlier version of this paper.
This study was a part of the first author's PhD thesis which was supported by a
grant from Mashhad University of Medical Sciences Research Councils.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitk&#x000e4;nen</surname><given-names>O</given-names></name><name><surname>Niskanen</surname><given-names>M</given-names></name><name><surname>Rehnberg</surname><given-names>S</given-names></name><name><surname>Hippel&#x000e4;inen</surname><given-names>M</given-names></name><name><surname>Hynynen</surname><given-names>M</given-names></name></person-group><article-title>Intrainstitutional prediction of outcome after cardiac surgery:
comparison between a locally derived model and the EuroSCORE</article-title><source>Eur J Cardiothorac Surg</source><year>2000</year><volume>18</volume><issue>6</issue><fpage>703</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">11113679</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Sharples</surname><given-names>LD</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Goldstone</surname><given-names>AR</given-names></name><etal/></person-group><article-title>EuroSCORE II</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>41</volume><issue>4</issue><fpage>734</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">22378855</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group><source>Harrison's principles of internal medicine</source><edition>15th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill Professional Publishing</publisher-name><year>2001</year></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Pinna Pintor</surname><given-names>P</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Baudet</surname><given-names>E</given-names></name><collab>EuroSCORE Study Group</collab></person-group><article-title>Does EuroSCORE work in individual European
countries?</article-title><source>Eur J Cardiothorac Surg</source><year>2000</year><volume>18</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10869937</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geissler</surname><given-names>HJ</given-names></name><name><surname>H&#x000f6;lzl</surname><given-names>P</given-names></name><name><surname>Marohl</surname><given-names>S</given-names></name><name><surname>Kuhn-R&#x000e9;gnier</surname><given-names>F</given-names></name><name><surname>Mehlhorn</surname><given-names>U</given-names></name><name><surname>S&#x000fc;dkamp</surname><given-names>M</given-names></name><etal/></person-group><article-title>Risk stratification in heart surgery: comparison of six score
systems</article-title><source>Eur J Cardiothorac Surg</source><year>2000</year><volume>17</volume><issue>4</issue><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">10773562</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Salamon</surname><given-names>R</given-names></name></person-group><article-title>European system for cardiac operative risk evaluation
(EuroSCORE)</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>16</volume><issue>1</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10456395</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>Vincentiis</surname><given-names>C</given-names></name><name><surname>Baudet</surname><given-names>E</given-names></name><etal/></person-group><article-title>Risk factors and outcome in European cardiac surgery: analysis of
the EuroSCORE multinational database of 19030 patients</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>15</volume><issue>6</issue><fpage>816</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">10431864</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>CH</given-names></name><name><surname>Reid</surname><given-names>C</given-names></name><name><surname>Yii</surname><given-names>M</given-names></name><name><surname>Rowland</surname><given-names>MA</given-names></name><name><surname>Mohajeri</surname><given-names>M</given-names></name><name><surname>Skillington</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Validation of the EuroSCORE model in Australia</article-title><source>Eur J Cardiothorac Surg</source><year>2006</year><volume>29</volume><issue>4</issue><fpage>441</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">16473519</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mir Mohammad Sadeghi</surname><given-names>SM</given-names></name><name><surname>Etesam Pour</surname><given-names>A</given-names></name><name><surname>Mir Mohammad Sadeghi</surname><given-names>FS</given-names></name><name><surname>Sadegh Pour</surname><given-names>M</given-names></name><name><surname>Saeidi</surname><given-names>M</given-names></name><name><surname>Nilforoush</surname><given-names>P</given-names></name><etal/></person-group><article-title>Is ESModel an appropriate scale to estimate the mortality before
the coronary bypass surgery in Iranian patients?</article-title><source>J Isfahan Medical School</source><year>2011</year><volume>28</volume><fpage>1118</fpage><lpage>1125</lpage></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamaati</surname><given-names>H</given-names></name><name><surname>Najafi</surname><given-names>A</given-names></name><name><surname>Kahe</surname><given-names>F</given-names></name><name><surname>Karimi</surname><given-names>Z</given-names></name><name><surname>Ahmadi</surname><given-names>Z</given-names></name><name><surname>Bolursaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of the EuroSCORE risk scoring system for patients
undergoing coronary artery bypass graft surgery in a group of Iranian
patients</article-title><source>Indian J Crit Care Med</source><year>2015</year><volume>19</volume><issue>10</issue><fpage>576</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">26628821</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>JV</given-names></name><name><surname>Naylor</surname><given-names>CD</given-names></name></person-group><article-title>Ready-made, recalibrated, or remodeled? Issues in the use of risk
indexes for assessing mortality after coronary artery bypass graft
surgery</article-title><source>Circulation</source><year>1999</year><volume>99</volume><issue>16</issue><fpage>2098</fpage><lpage>2104</lpage><pub-id pub-id-type="pmid">10217648</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>S</given-names></name><name><surname>Fischhoff</surname><given-names>B</given-names></name><name><surname>Phillips</surname><given-names>LD</given-names></name></person-group><chapter-title>Calibration of probabilities: the state of the art to
1980</chapter-title><person-group person-group-type="editor"><name><surname>Kahneman</surname><given-names>D</given-names></name><name><surname>Slovic</surname><given-names>P</given-names></name><name><surname>Tversky</surname><given-names>A</given-names></name></person-group><source>Judgement under uncertainty: heuristics and biases</source><publisher-loc>New York</publisher-loc><publisher-name>Cambridge University Press</publisher-name><year>1982</year></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Hosmer Jr</surname><given-names>DW</given-names></name></person-group><article-title>A review of goodness of fit statistics for use in the development
of logistic regression models</article-title><source>Am J Epidemiol</source><year>1982</year><volume>115</volume><issue>1</issue><fpage>92</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">7055134</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname><given-names>S</given-names></name><name><surname>Rodrigues</surname><given-names>R</given-names></name><name><surname>Tralh&#x000e3;o</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>C</given-names></name><name><surname>Marques</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of perioperative mortality risk in patients with
infective endocarditis undergoing cardiac surgery: performance of the
EuroSCORE I and II logistic models</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2016</year><volume>22</volume><issue>2</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">26547083</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>RE</given-names></name></person-group><article-title>The STS Cardiac Surgery National Database: an
update</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>59</volume><issue>6</issue><fpage>1376</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">7771813</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson Jr</surname><given-names>TB</given-names></name><name><surname>Dziuban Jr</surname><given-names>SW</given-names></name><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Eiken</surname><given-names>MC</given-names></name><name><surname>Shroyer</surname><given-names>AL</given-names></name><name><surname>Pairolero</surname><given-names>PC</given-names></name><etal/></person-group><article-title>The STS National Database: current changes and challenges for the
new millennium. Committee to Establish a National Database in Cardiothoracic
Surgery, The Society of Thoracic Surgeons</article-title><source>Ann Thorac Surg</source><year>2000</year><volume>69</volume><issue>3</issue><fpage>680</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">10750744</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochrane</surname><given-names>AL</given-names></name></person-group><article-title>Archie Cochrane in his own words. Selections arranged from his
1972 introduction to "Effectiveness and Efficiency: Random Reflections on
the Health Services" 1972</article-title><source>Control Clin Trials</source><year>1989</year><volume>10</volume><issue>4</issue><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">2691208</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parolari</surname><given-names>A</given-names></name><name><surname>Pesce</surname><given-names>LL</given-names></name><name><surname>Trezzi</surname><given-names>M</given-names></name><name><surname>Cavallotti</surname><given-names>L</given-names></name><name><surname>Kassem</surname><given-names>S</given-names></name><name><surname>Loardi</surname><given-names>C</given-names></name><etal/></person-group><article-title>EuroSCORE performance in valve surgery: a
meta-analysis</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>3</issue><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">20172129</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barili</surname><given-names>F</given-names></name><name><surname>Pacini</surname><given-names>D</given-names></name><name><surname>Capo</surname><given-names>A</given-names></name><name><surname>Rasovic</surname><given-names>O</given-names></name><name><surname>Grossi</surname><given-names>C</given-names></name><name><surname>Alamanni</surname><given-names>F</given-names></name><etal/></person-group><article-title>Does EuroSCORE II perform better than its original versions? A
multicentre validation study</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>1</issue><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">23028171</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebreton</surname><given-names>G</given-names></name><name><surname>Merle</surname><given-names>S</given-names></name><name><surname>Inamo</surname><given-names>J</given-names></name><name><surname>Hennequin</surname><given-names>JL</given-names></name><name><surname>Sanchez</surname><given-names>B</given-names></name><name><surname>Rilos</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Limitations in the inter-observer reliability of EuroSCORE: what
should change in EuroSCORE II?</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>6</issue><fpage>1304</fpage><lpage>1308</lpage><pub-id pub-id-type="pmid">21497102</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borracci</surname><given-names>RA</given-names></name><name><surname>Rubio</surname><given-names>M</given-names></name><name><surname>Celano</surname><given-names>L</given-names></name><name><surname>Ingino</surname><given-names>CA</given-names></name><name><surname>Allende</surname><given-names>NG</given-names></name><name><surname>Ahuad Guerrero</surname><given-names>RA</given-names></name></person-group><article-title>Prospective validation of EuroSCORE II in patients undergoing
cardiac surgery in Argentinean centres</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2014</year><volume>18</volume><issue>5</issue><fpage>539</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">24491683</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Pullan</surname><given-names>M</given-names></name><name><surname>Fabri</surname><given-names>B</given-names></name><name><surname>McShane</surname><given-names>J</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Mediratta</surname><given-names>N</given-names></name><etal/></person-group><article-title>Validation of EuroSCORE II in a modern cohort of patients
undergoing cardiac surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2013</year><volume>43</volume><issue>4</issue><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">22833541</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>QQ</given-names></name><name><surname>Qiao</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>XW</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><etal/></person-group><article-title>Performance of EuroSCORE II in patients who have undergone heart
valve surgery: a multicentre study in a Chinese population</article-title><source>Eur J Cardiothorac Surg</source><year>2014</year><volume>45</volume><issue>2</issue><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">23677902</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>PE</given-names></name><name><surname>Eug&#x000e9;nio</surname><given-names>L</given-names></name><name><surname>Ferr&#x000e3;o de Oliveira</surname><given-names>J</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name></person-group><article-title>Mortality risk prediction in coronary surgery: a locally
developed model outperforms external risk models</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2007</year><volume>6</volume><issue>4</issue><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">17669892</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hekmat</surname><given-names>K</given-names></name><name><surname>Raabe</surname><given-names>A</given-names></name><name><surname>Kroener</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>U</given-names></name><name><surname>Suedkamp</surname><given-names>M</given-names></name><name><surname>Geissler</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Risk stratification models fail to predict hospital costs of
cardiac surgery patients</article-title><source>Z Kardiol</source><year>2005</year><volume>94</volume><issue>11</issue><fpage>748</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">16258777</pub-id></element-citation></ref></ref-list></back></article>